Introduction
There have been few cases of active acromegaly in which serum basal growth hormone (GH) levels are within the normal range (1) (2) (3) (4) . In these patients, an unusual sensitivity to their ownGHat the peripheral tissue has been speculated (2) . In the present paper, we report a case of pituitary gigantism associated with hyperprolactinemia, in which non-pulsatile secretion of GHin small amounts may induce hypersecretion of insulin-like growth factor-I (IGF-I).
Case Report
A 39-year-old male was referred to our department on September 1992 because of overgrowth, acromegalic appearance and obesity. His father had diabetes mellitus and his mother had hypertension. The patient himself was diagnosed with diabetes mellitus at the age of 36. On physical examination, the patient was 197 cm tall and weighed 140 kg. His blood pressure was 140/92 mmHg.He had a large frame and coarse facial features with a prominent jaw. The visual field was normal. His hands and feet were prominently enlarged (Fig. 1 ) . As shown in Table 1 , laboratory data revealed mildly elevated levels of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), choline esterase, uric acid, phosphate and triglyceride. Cauliflower-like tuftings of the finger bones were noted. The heel pad thickness was 25 mm. Skull x-ray revealed an enlargement and a double floor of the sella turcica (Fig. 2) . Magnetic resonance imaging of the brain showed a pituitary macroadenoma with a sphenoidal extension (Fig. 3) . Table 2 shows serum basal hormonelevels on admission.
Serum GH levels determined by both radioimmunoassay (RIA) and immunoradiometric assay (IRMA) (5) were within the normal ranges. The amount of 24h urinary GHexcretion was 4.9 pg/mg à" creatinine (normal: 1.7-8.5 pg/mg creatinine). Serum IGF-I and prolactin levels were elevated with slightly reduced testosterone. Oral glucose loading test showed an impaired glucose tolerance and normal responses of serum insulin (Table 3) . Serum GHlevels during glucose loading were less than 1.5 ng/ml. As shown in Table 4 , serum GHresponses to insulin-induced hypoglycemia or GHreleasing factor (GRF) were blunted. The administration of thyrotropin-releasing hormone (TRH) evoked a small rise in serum GH, but the administration of luteinizing hormone-releasing hormone (LHRH)
did not evoke an increase in serum GH.The oral administration of 1-dopa and bromocriptine decreased serum GHlevel. The subcutaneous injection ofoctreotide decreased serum GHlevel. Frequent blood samplings during the day and nocturnal sleep showed non-pulsatile secretion of GH (Fig. 4) . Serum IGF-I levels were elevated from 599 ng/ml to 751 ng/ml after GH administration for 3 days. The patient was diagnosed with acromegalic gigantism and underwent transsphenoidal surgery in January 1993. The histological diagnosis of the resected tumor was chromophobe adenoma. Most of the adenoma cells were positive for immunostaining of prolactin but not for GH (Fig. 5) . After surgery, serum prolactin levels were slightly decreased and serum testosterone was increased. However,serum GHand IGF-I levels were unchanged. Therefore, since February 1993, the patient has received 10 mgof bromocriptine daily in two divided doses. Serum prolactin levels decreased from 41.9 to 0.5 ng/ml, and serum testosterone levels rose further without any considerable change in serum GHand IGF-I levels. He subsequently received subcutaneous injections of octreotide, a somatostatin analogue, 300 jig daily in three divided doses. Serum GHlevels were decreased from 1.73 to 0.31 ng/ml with a concomitant decrease in serum IGF-I levels from 5 15 to 254 ng/ml (Fig. 6 ).
Methods Serum GHlevels were determined by commercial RIA and IRMA kits provided by Dinabot (Tokyo) and Daiichi RI (Tokyo), respectively. Sensitivity ofGH IRMAassay was less than 0.1 ng/ml. Serum IGF-I levels were also determined by commercial RIA kit (Ciba-Corning, Tokyo). To determine the secretory profile of GH, venous blood was withdrawn from the indwelling catheter in the right forearm at 10 min intervals during the daytime (0900-1300 h), and at 20 min intervals during nocturnal sleep (2100-0300 h). To determine the GH dependency of serum IGF-I, 4 I.U. recombinant human GH (Sumitomo Pharmaceutical Co., Tokyo) was administered s.c. at 2200 h for 3 days. After the subcutaneous injection of 100 \ig octreotide, serum GHlevels were determined during an 8-hour period.
Discussion
The present case had clinical features of acromegaly and gigantism. The basal levels of serum GHwere within the normal range. However, the secretory dynamics of GHin the patient were considered to be qualitatively abnormal even at the lower levels, since insulin-induced hypoglycemia did not evoke GHrelease, nocturnal sleep did not induce GHrelease, and GH PRL r* 1 Bromocriptine 5mg/day ,GF.! Testosterone (ng/ml) (ng/ml) t 1^oTjg/day (ng/ml) (ng/ml) dopaminergic agents suppressed and TRHevoked GHsecretion. Therefore, we concluded that the patient had active pituitary gigantism and acromegaly. There are several rare cases of active acromegaly with minimally elevated GH (1-4).
Brockmeier et al (6) reported that 8 out of 216 patients with acromegaly had "normal" basal serum GHlevels (equal to or less than 5 ng/ml). However, all their patients showedabnormal GHresponses during oral glucose loading, especially serum GHlevels were not suppressed below 2 ng/ml. The present case is the lowest basal level of serum GHassociated with active acromegalyever reported. Several authors have investigated the causes of relatively low GHsecretion by some pituitary adenomas. Mashiter et al (7) postulated that GHwas digested in the lyposome in a patient with a large pituitary tumor but low GHsecretion. In another report, somatostatin synthesis was shown to occur in some pituitary tumor cells, which could result in diminished GH release (4) . Pituitary apoplexy and burned out acromegaly may also be considered as the cause of reduced GHsecretion by tumors. However, the present case had no history of headache or visual disturbances. MRIshowedthe pituitary as a solid mass, suggesting that pituitary apoplexy is unlikely. Elevated IGF-I levels in the present patient seem to be dependent on the GHlevel, since the treatment with octreotide decreased both GHand IGF-I levels, and IGF-I levels were slightly elevated after GHadministration. Barkan et al (8) have reported an excellent log dose-response correlation between integrated serum GHand IGF-I concentrations in patients with acromegaly. A low but constant level of GHthroughout the day might represent a significant increase in GHproduction and induce IGF-I production. The non-pulsatile nature of the GH secretion observed in our patient has been reported to be more potent in inducing IGF-I production in the liver than the pulsatile GHsecretion (9) . However, the amount of urinary GH excretion was within the normal range in the present case. Therefore, a possible reason for elevated serum IGF-I, in spite of the normal serum GHlevel, is the enhanced tissue sensitivity to GH, although the IGF-I/GH ratio greatly varies among acromegaly cases (2). Another feasible explanation for the discrepancy between serum IGF-I and serum GHlevels is that the GHmolecule of the patient is immunologically inactive but biologically active. We have determined GHlevels by two immunological methods, RIA and IRMA,using different antibodies recognizing different epitopes of the molecule. Theresults of both assays were comparable, suggesting that GHis immunologically potent. Determination of biological activity is presently in progress.
Another prospect maybe molecular heterogeneity of circulating GH. The biologically active GH-like molecule in the circulation might induce IGF-I production. There is one report of prolactin-producing pituitary adenoma presenting active acromegaly with elevated IGF-I and undetectable GHlevels ( 1 0). Hyperprolactinemia was also observed in the present case. However, bromocriptine effectively reduced prolactin levels in our patient but did not affect IGF-I levels at all. GH receptor antibodies with GH-like activities have been described in a patient with acromegaly without detectable pituitary or extracranial tumor (1 1). It is unlikely that our patient had GHlike antibodies, since octreotide therapy reduced GHlevels and normalized IGF-I.
Although immunohistochemical staining for GH of the pituitary adenoma was negative in the available specimens, we still consider the possibility that the patient had some GH producing cells elsewhere in the tumor, since it was only possible to partially resect the pituitary tumor due to bleeding at the time of the operation. In conclusion, in the present case, non-pulsatile continuous secretion ofGH, even though in small amounts, was related to the elevated level of IGF-I and caused clinical acromegalic gigantism.
